We use cookies to improve your experience. By continuing to browse this site, you accept our cookie policy.×
Skip main navigation
Open Drawer MenuClose Drawer Menu
Aging Health
Bioelectronics in Medicine
Biomarkers in Medicine
Breast Cancer Management
CNS Oncology
Colorectal Cancer
Concussion
Epigenomics
Future Cardiology
Future Medicine AI
Future Microbiology
Future Neurology
Future Oncology
Future Rare Diseases
Future Virology
Hepatic Oncology
HIV Therapy
Immunotherapy
International Journal of Endocrine Oncology
International Journal of Hematologic Oncology
Journal of 3D Printing in Medicine
Lung Cancer Management
Melanoma Management
Nanomedicine
Neurodegenerative Disease Management
Pain Management
Pediatric Health
Personalized Medicine
Pharmacogenomics
Regenerative Medicine
Drug Evaluation

Bevacizumab as first-line therapy for glioblastoma

    David Piccioni

    Department of Neurology, University of California, UCLA Department of Neurology, Neuro-Oncology Program, 710 Westwood Plaza 1-230, Los Angeles, CA 90024, USA

    Search for more papers by this author

    ,
    Albert Lai

    Department of Neurology, University of California, UCLA Department of Neurology, Neuro-Oncology Program, 710 Westwood Plaza 1-230, Los Angeles, CA 90024, USA

    Search for more papers by this author

    ,
    Phioanh Nghiemphu

    Department of Neurology, University of California, UCLA Department of Neurology, Neuro-Oncology Program, 710 Westwood Plaza 1-230, Los Angeles, CA 90024, USA

    Search for more papers by this author

    &
    Timothy Cloughesy

    * Author for correspondence

    Department of Neurology, University of California, UCLA Department of Neurology, Neuro-Oncology Program, 710 Westwood Plaza 1-230, Los Angeles, CA 90024, USA.

    Search for more papers by this author

    Email the corresponding author at tcloughesy@mednet.ucla.edu

    Published Online:15 Aug 2012https://doi.org/10.2217/fon.12.81

    Abstract

    Bevacizumab is a monoclonal antibody that binds and neutralizes VEGF. Bevacizumab is currently indicated as monotherapy for recurrent glioblastoma. Recent data from Phase II trials of bevacizumab as first-line therapy for glioblastoma have been promising, and have led to two Phase III trials evaluating the use of bevacizumab as first-line therapy when combined with radiation and temozolomide. Potential complications relating to interpretation of the results of these Phase III studies include the crossover use of bevacizumab upon recurrence in the placebo arm. Recently published single-arm evaluations of adding bevacizumab to standard first-line therapy in glioblastoma multiforme have shown an improvement in progression-free survival and overall survival when compared with historical controls obtained prior to widespread use of bevacizumab in recurrent glioblastoma multiforme. When these data are compared with more contemporary studies from the bevacizumab era, the improvement in progression-free survival seems to be maintained but the impact on overall survival with first-line bevacizumab therapy seems less clear. Bevacizumab therapy alters the imaging characteristics of glioblastoma, and new criteria have been established to assess treatment response and progression in the setting of widespread bevacizumab use.

    Papers of special note have been highlighted as: ▪ of interest ▪▪ of considerable interest

    References

    • 1  Folkman J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med.285(21),1182–1186 (1971).
      Medline CASGoogle Scholar
    • 2  Brem H, Piantadosi S, Burger PC et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. Lancet345(8956),1008–1012 (1995).
      Medline CASGoogle Scholar
    • 3  Westphal M, Ram Z, Riddle V, Hilt D, Bortey E. Gliadel wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trial. Acta Neurochir. (Wien)148(3),269–275; discussion 275 (2006).
      Medline CASGoogle Scholar
    • 4  Stupp R, Mason WP, Van Den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med.352(10),987–996 (2005).
      Medline CASGoogle Scholar
    • 5  Stupp R, Hegi ME, Mason WP et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised Phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol.10(5),459–466 (2009).
      Medline CASGoogle Scholar
    • 6  Friedman HS, Prados MD, Wen PY et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J. Clin. Oncol.27(28),4733–4740 (2009).▪ This study provided evidence that led to the US FDA approval of bevacizumab in recurrent glioblastoma.
      Medline CASGoogle Scholar
    • 7  Kreisl TN, Kim L, Moore K et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J. Clin. Oncol.27(5),740–745 (2009).▪ This study provided evidence that led to the FDA approval of bevacizumab in recurrent glioblastoma.
      Medline CASGoogle Scholar
    • 8  Lu JF, Bruno R, Eppler S, Novotny W, Lum B, Gaudreault J. Clinical pharmacokinetics of bevacizumab in patients with solid tumors. Cancer Chemother. Pharmacol.62(5),779–786 (2008).
      Medline CASGoogle Scholar
    • 9  Moen MD. Bevacizumab: in previously treated glioblastoma. Drugs70(2),181–189 (2010).
      Medline CASGoogle Scholar
    • 10  Lin YS, Nguyen C, Mendoza JL et al. Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor. J. Pharmacol. Exp. Ther.288(1),371–378 (1999).
      Medline CASGoogle Scholar
    • 11  Stark-Vance V. Bevacizumab and CPT-11 in the treatment of relapsed malignant glioma. Neuro Oncol.7(3), Abstract 342 (2005).
      Google Scholar
    • 12  Shih T, Lindley C. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. Clin. Ther.28(11),1779–1802 (2006).▪▪ Excellent review of the pharmacology of bevacizumab.
      Medline CASGoogle Scholar
    • 13  Chinot OL, De La Motte Rouge T, Moore N et al. AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme. Adv. Ther.28(4),334–340 (2011).
      Medline CASGoogle Scholar
    • 14  Wang Y, Fei D, Vanderlaan M, Song A. Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro.Angiogenesis7(4),335–345 (2004).
      Medline CASGoogle Scholar
    • 15  Kim KJ, Li B, Winer J et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo.Nature362(6423),841–844 (1993).
      Medline CASGoogle Scholar
    • 16  Lai A, Tran A, Nghiemphu PL et al. Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J. Clin. Oncol.29(2),142–148 (2011).▪▪ Showed an improved progression-free survival with first-line bevacizumab.
      Medline CASGoogle Scholar
    • 17  Narayana A, Gruber D, Kunnakkat S et al. A clinical trial of bevacizumab, temozolomide, and radiation for newly diagnosed glioblastoma. J. Neurosurg.116(2),341–345 (2012).
      Medline CASGoogle Scholar
    • 18  Narayana A, Kelly P, Golfinos J et al. Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival. J. Neurosurg.110(1),173–180 (2009).
      MedlineGoogle Scholar
    • 19  Vredenburgh JJ, Desjardins A, Reardon DA et al. The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma. Clin. Cancer Res.17(12),4119–4124 (2011).
      Medline CASGoogle Scholar
    • 20  Grossman SA, Ye X, Piantadosi S et al. Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States. Clin. Cancer Res.16(8),2443–2449 (2010).▪ Excellent discussion of survival in historical and recent trials.
      Medline CASGoogle Scholar
    • 21  Levin VA, Crafts DC, Norman DM, Hoffer PB, Spire JP, Wilson CB. Criteria for evaluating patients undergoing chemotherapy for malignant brain tumors. J. Neurosurg.47(3),329–335 (1977).
      Medline CASGoogle Scholar
    • 22  Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG. Response criteria for Phase II studies of supratentorial malignant glioma. J. Clin. Oncol.8(7),1277–1280 (1990).
      Medline CASGoogle Scholar
    • 23  Quant EC, Wen PY. Response assessment in neuro-oncology. Curr. Oncol. Rep.13(1),50–56 (2011).
      MedlineGoogle Scholar
    • 24  Wen PY, Macdonald DR, Reardon DA et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J. Clin. Oncol.28(11),1963–1972 (2010).▪▪ Excellent discussion of the Response Assessment in Neuro-Oncology (RANO) criteria.
      MedlineGoogle Scholar
    • 25  Brandsma D, Stalpers L, Taal W, Sminia P, Van Den Bent MJ. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol.9(5),453–461 (2008).
      MedlineGoogle Scholar
    • 26  Brandes AA, Franceschi E, Tosoni A et al.MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J. Clin. Oncol.26(13),2192–2197 (2008).
      MedlineGoogle Scholar
    • 27  Brandsma D, Van Den Bent MJ. Pseudoprogression and pseudoresponse in the treatment of gliomas. Curr. Opin Neurol.22(6),633–638 (2009).
      MedlineGoogle Scholar
    • 28  Prados M, Cloughesy T, Samant M et al. Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab. Neuro Oncol.13(1),143–151 (2011).
      Medline CASGoogle Scholar
    • 29  Grossman SA, Ye X, Chamberlain M et al. Talampanel with standard radiation and temozolomide in patients with newly diagnosed glioblastoma: a multicenter Phase II trial. J. Clin. Oncol.27(25),4155–4161 (2009).
      Medline CASGoogle Scholar
    • 30  Butowski N, Chang SM, Junck L et al. A Phase II clinical trial of poly-ICLC with radiation for adult patients with newly diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05). J. Neurooncol.91(2),175–182 (2009).
      Medline CASGoogle Scholar
    • 31  Reardon DA, Fink KL, Mikkelsen T et al. Randomized Phase II study of cilengitide, an integrin-targeting arginine–glycine–aspartic acid peptide, in recurrent glioblastoma multiforme. J. Clin. Oncol.26(34),5610–5617 (2008).
      Medline CASGoogle Scholar
    • 32  Gerber HP, Ferrara N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res.65(3),671–680 (2005).
      Medline CASGoogle Scholar
    • 33  Nghiemphu PL, Green RM, Pope WB, Lai A, Cloughesy TF. Safety of anticoagulation use and bevacizumab in patients with glioma. Neuro Oncol.10(3),355–360 (2008).
      MedlineGoogle Scholar
    • 34  Norden AD, Bartolomeo J, Tanaka S et al. Safety of concurrent bevacizumab therapy and anticoagulation in glioma patients. J. Neurooncol.106(1),121–125 (2012).
      Medline CASGoogle Scholar
    • 35  Narayana A, Golfinos JG, Fischer I et al. Feasibility of using bevacizumab with radiation therapy and temozolomide in newly diagnosed high-grade glioma. Int. J. Radiat. Oncol. Biol. Phys.72(2),383–389 (2008).
      Medline CASGoogle Scholar
    • 36  Vredenburgh JJ, Desjardins A, Kirkpatrick JP et al. Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme. Int. J. Radiat. Oncol. Biol. Phys.82(1),58–66 (2010).
      MedlineGoogle Scholar
    • 101  CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2004–2008 (23 March 2012 Revision). www.cbtrus.org/2012-NPCR-SEER/CBTRUS_Report_2004-2008_3-23-2012.pdf
      Google Scholar
    • 102  RTOG 0825. Phase III Double-blinded Placebo-Controlled Trial of Conventional Concurrent Chemoradiation and Adjuvant Temozolomide Plus Bevacizumab Versus Conventional Concurrent Chemoradiation and Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma. www.rtog.org/ClinicalTrials/ProtocolTable/StudyDetails.aspx?study=0825
      Google Scholar
    • 103  Avastin Prescribing Information. Genentech, Inc. September 2011. www.gene.com/gene/products/information/pdf/avastin-prescribing.pdf
      Google Scholar